Follow the Pundits

Tag: Madrigal Earnings

Madrigal Pharmaceuticals MDGL illustration showing Baker Bros.' $35M purchase, Rezdiffra's $1.1B sales milestone and 8.9 FunStock Index.

Madrigal Pharmaceuticals ($MDGL): Baker Bros. Buys $35M as Rezdiffra Hits Blockbuster Status 🧪🚀

🧬 Madrigal Pharmaceuticals ($MDGL) is turning scientific innovation into commercial success. Baker Bros. reportedly purchased another $35 million in shares as Rezdiffra surpassed $1.1 billion in year-to-date sales and Madrigal delivered its first profitable quarter. With 50% revenue growth, expanding MASH treatment demand and substantial institutional sponsorship, the investment case is compelling—but competition and single-drug concentration remain real risks. FunStock Index™: 8.9/10.

Read entire article

Tags: Baker Bros, Baker Bros Advisors, Biotech Stocks, Biotech Valuation, Biotechnology Investing, Blockbuster Drug, FDA Approved Drugs, featured-hedge-funds, Felix Baker, FUNanc1al, FunStock Index, FunStock Method, Growth Investing, Hedge Funds, hub-hedge, hub-insiders, Insider Buying, Insider Purchases, Institutional Ownership, Julian Baker, Liver Disease, Madrigal Earnings, Madrigal Pharmaceuticals, Madrigal Stock, MASH, MASH Therapy, MASH Treatment, MDGL, MDGL Stock Analysis, Metabolic Dysfunction Associated Steatohepatitis, NASDAQ MDGL, Pharmaceutical Stocks, Q3 2026 Earnings, Resmetirom, Rezdiffra, Short Interest